Hansa Biopharma AB (HNSA) AI Stock Analysis

• Market Cap: kr3.40B
• Dividend Yield: N/A
• Average Volume (3M): 792.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: -5.69%
• EPS Growth: 21.58%
• Country: SE
• Employees: 138
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.75
• Shares Outstanding: 101,763,220
• 10 Day Avg. Volume: 714,369
• 30 Day Avg. Volume: 792,961
• PEG Ratio: 0.16
• Price to Book (P/B): -4.18
• Price to Sales (P/S): 14.38
• P/FCF Ratio: -3.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr106.50
• Price Target Upside: 281.17% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: kr31.00 ▲(10.95% Upside)

Hansa Biopharma AB's overall stock score reflects significant financial challenges, including negative equity and cash flow issues, which weigh heavily on the score. Technical analysis provides mixed signals, with some positive momentum but also potential overbought conditions. The valuation is weak due to a negative P/E ratio, indicating ongoing profitability issues. Despite positive developments from the earnings call, such as a successful Phase 3 trial and a strong cash position, these are not enough to offset the financial and valuation concerns.

Positive Factors

Successful Phase 3 Trial

The successful Phase 3 trial demonstrates the potential of Hansa's lead product, imlifidase, in addressing unmet medical needs, paving the way for regulatory approval and future revenue growth.

U.S. Market Opportunity

The U.S. market offers a substantial growth opportunity for Hansa Biopharma, with a large patient base and potential product launch, enhancing long-term revenue prospects.

Strong Cash Position

A robust cash position provides Hansa Biopharma with financial flexibility to invest in R&D and support its strategic initiatives, ensuring sustainability and growth.

Negative Factors

Decline in Revenue

A significant decline in revenue indicates challenges in market penetration and sales execution, which could hinder financial performance and growth prospects.

Challenges in Key Markets

Operational challenges in Germany and Spain highlight regional market risks and regulatory hurdles that could impact sales and strategic expansion.

Increased Operating Loss

Rising operating losses reflect ongoing financial strain, limiting the company's ability to invest in growth initiatives and potentially affecting long-term viability.

Hansa Biopharma AB Business Overview & Revenue Model

Company Description

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

How the Company Makes Money

Hansa Biopharma generates revenue primarily through the commercialization of its therapeutics, particularly imlifidase, which is being marketed for use in kidney transplantation and other indications. The company may also earn revenue through strategic partnerships and collaborations with larger pharmaceutical firms, which can involve upfront payments, milestone payments based on developmental progress, and royalties from product sales. Additionally, Hansa Biopharma is likely to engage in research agreements and licensing deals that can provide supplementary income as it expands its pipeline of enzyme-based therapies.

Hansa Biopharma AB Financial Statement Overview

Summary

Hansa Biopharma AB faces significant financial challenges, with consistent net losses, negative equity, and cash flow difficulties. Despite some revenue growth, high leverage and ongoing operational inefficiencies pose risks to financial stability.

Income Statement

Hansa Biopharma AB's income statement reflects substantial challenges, with consistent net losses and negative EBIT and EBITDA margins. The gross profit margin is relatively higher, indicating some ability to cover variable costs, but the net profit margin remains negative. Revenue has shown some growth over the years, yet profitability remains elusive.

Balance Sheet

The balance sheet indicates significant financial stress with negative stockholders' equity, suggesting more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, while high total debt levels pose a risk. The equity ratio is negative, further highlighting financial instability.

Cash Flow

Cash flow analysis reveals negative operating cash flows and free cash flows, indicating challenges in generating cash from operations. Although financing activities have provided cash inflows, the free cash flow to net income ratio remains unfavorable, reflecting ongoing operational cash deficits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	178.61M	171.32M	134.09M	154.53M	33.88M	6.10M
Gross Profit	106.22M	87.76M	70.95M	116.05M	18.45M	5.10M
EBITDA	-479.13M	-642.07M	-714.55M	-554.26M	-538.83M	-413.08M
Net Income	-640.63M	-807.24M	-831.72M	-611.13M	-548.28M	-420.85M
Balance Sheet
Total Assets	741.11M	800.64M	1.02B	1.69B	1.01B	1.43B
Cash, Cash Equivalents and Short-Term Investments	252.07M	405.28M	732.06M	1.50B	888.96M	1.38B
Total Debt	923.89M	1.08B	866.77M	791.09M	35.38M	5.04M
Total Liabilities	1.30B	1.39B	1.19B	1.08B	255.24M	192.37M
Stockholders Equity	-560.74M	-589.83M	-167.88M	602.91M	757.57M	1.24B
Cash Flow
Free Cash Flow	-560.72M	-675.00M	-755.94M	-506.06M	-483.57M	-290.57M
Operating Cash Flow	-560.09M	-674.88M	-755.65M	-502.73M	-481.17M	-290.27M
Investing Cash Flow	-628.00K	-116.00K	-284.00K	229.31M	-2.40M	182.53M
Financing Cash Flow	259.79M	346.81M	-7.54M	1.12B	-4.86M	1.07B

Hansa Biopharma AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HNSA, the sentiment is Negative. The current price of 27.94 is below the 20-day moving average (MA) of 32.66, below the 50-day MA of 31.93, and below the 200-day MA of 28.41, indicating a bearish trend. The MACD of 0.64 indicates Positive momentum. The RSI at 36.13 is Neutral, neither overbought nor oversold. The STOCH value of 41.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:HNSA.

Hansa Biopharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	76 Outperform	kr3.03B	4.60	167.77%	―	2687.51%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BINV	47 Neutral	kr1.84B	-5.65	-36.52%	―	533.73%	20.92%
XSPRAY	47 Neutral	kr1.23B	-5.06	-35.03%	―	―	25.14%
VICO	45 Neutral	kr2.82B	-5.34	-71.87%	―	-91.85%	-6.65%
HNSA	41 Neutral	kr3.40B	-3.14	―	―	-5.69%	21.58%
CANTA	31 Underperform	kr1.10B	8.07	81.19%	―	―	―

Hansa Biopharma AB Corporate Events

Hansa Biopharma to Present at Major Healthcare Conferences

Hansa Biopharma announced its CEO, Renée Aguiar-Lucander, will participate in key discussions at the Jefferies Global Healthcare Conference in London and the DNB Carnegie’s 16th Annual Nordic Healthcare Conference in Oslo. These engagements are significant for Hansa Biopharma as they provide a platform to showcase its innovative treatments and strengthen its industry positioning, potentially impacting stakeholder relations and market perception.

Hansa Biopharma Hosts Virtual Event on Imlifidase Phase 3 Results

Hansa Biopharma AB announced a virtual event featuring transplant experts to discuss the Phase 3 results of their imlifidase treatment for highly sensitized kidney transplant patients. The event aims to provide insights into the clinical relevance of these results and their potential impact on the standard of care for transplant patients, highlighting the company’s commitment to addressing the needs of this challenging patient group.

Hansa Biopharma Engages in Key Industry Conferences

Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, and CFO, Evan Ballantyne, will attend the 2025 Truist Securities Biopharma Symposium in New York. Aguiar-Lucander will also present at the Stifel 2025 Healthcare Conference and the SEB Healthcare Seminar 2025. These appearances highlight Hansa’s active engagement with the investment community and underscore its strategic focus on expanding its presence in the biopharmaceutical industry.

Hansa Biopharma Expands Share Capital with New Share Issue

Hansa Biopharma has increased its registered share capital and the number of shares and votes by issuing 17,000,000 new ordinary shares, bringing the total to 101,763,222 shares and votes. This move reflects the company’s strategic efforts to strengthen its financial position and support its ongoing research and development initiatives in the biopharmaceutical industry.

Hansa Biopharma’s Imlifidase Achieves Key Milestone in U.S. Phase 3 Trial

Hansa Biopharma announced that its drug imlifidase successfully met the primary endpoint in a pivotal U.S. Phase 3 trial for kidney transplantation, showing significant improvement in kidney function compared to the control group. The company plans to file a Biologic License Application with the FDA by the end of 2025, potentially enhancing its market position in the U.S. Additionally, Hansa reported a 25.4% increase in year-to-date product sales of IDEFIRIX, reflecting strong market performance. The company also completed a directed share issue raising approximately 671.5 MSEK to support its operational expansion and regulatory submissions.

Hansa Biopharma Hosts Event on Imlifidase Phase 3 Results

Hansa Biopharma AB announced a virtual event featuring renowned transplant surgeons to discuss the clinical relevance of the US Phase 3 ConfIdeS study results on Imlifidase, a treatment for highly sensitized kidney transplant patients. This event underscores Hansa’s commitment to advancing transplantation medicine and highlights the potential impact of Imlifidase on improving transplant accessibility and outcomes for patients with limited donor options.

Hansa Biopharma’s Imlifidase Enables Breakthrough in Gene Therapy for Crigler-Najjar Syndrome

Hansa Biopharma and Genethon have announced successful results from a clinical trial using imlifidase as a pretreatment for gene therapy in a patient with Crigler-Najjar syndrome who is immune to AAV vectors. This breakthrough could potentially expand gene therapy options for patients previously ineligible due to immunity, marking a significant advancement in the treatment of rare genetic diseases.

Hansa Biopharma to Discuss Q3 2025 Results in Upcoming Conference Call

Hansa Biopharma announced it will host a conference call to discuss its Q3 2025 interim results on October 30, 2025. The call, led by key executives, will cover the company’s financial performance and provide updates on its business and pipeline, reflecting its ongoing commitment to addressing serious medical needs in its field.

Hansa Biopharma CEO to Participate in Key Industry Conferences

Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will participate in two significant industry events: Optimum’s 17th Annual Healthcare Investor Conference and Nordic Life Science Days 2025. These engagements highlight Hansa’s active role in shaping industry discussions on exit strategies and future financing trends, potentially enhancing its visibility and influence in the biopharmaceutical sector.

Hansa Biopharma Announces Directed Share Issue for Nasdaq Stockholm Trading

Hansa Biopharma announced a directed share issue of 17 million ordinary shares to facilitate their trading on Nasdaq Stockholm, with trading expected to commence around October 6, 2025. This move is part of Hansa’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its industry positioning and stakeholder interests.

Hansa Biopharma Raises USD 71 Million to Boost U.S. Market Efforts

Hansa Biopharma has successfully raised approximately USD 71 million through a directed share issue of 17 million shares, aimed at Swedish and international institutional investors. The proceeds will support the company’s strategic initiatives, including a potential Biologic License Application filing with the FDA for imlifidase, and enhancing its medical and commercial capabilities in the U.S. This capital raise is a strategic move to strengthen Hansa’s market position and prepare for the potential U.S. launch of imlifidase, reflecting strong investor confidence and expanding its shareholder base.

Hansa Biopharma Plans USD 60 Million Share Issue to Boost U.S. Market Efforts

Hansa Biopharma AB announced its intention to raise approximately USD 60 million through a directed share issue aimed at Swedish and international institutional investors. The funds will support the company’s strategic initiatives, including the potential filing of a Biologic License Application with the FDA and preparations for the commercial launch of imlifidase in the U.S. The decision for a directed share issue, as opposed to a rights issue, was made to ensure timely capital acquisition and to attract strategic biotechnology investors, reflecting the company’s proactive approach to strengthening its market position.

Hansa Biopharma’s Imlifidase Shows Promise in Gene Therapy for Crigler-Najjar Syndrome

Hansa Biopharma announced that Genethon will present preliminary data from a Phase 2 trial of imlifidase as a pre-treatment for gene therapy in patients with severe Crigler-Najjar syndrome at the ESGCT congress. The trial, which aims to address the barrier of anti-AAV antibodies in gene therapy, could significantly impact the treatment landscape for this ultra-rare disease, potentially enabling more patients to benefit from gene therapies.

Hansa Biopharma Reports Positive Phase 3 Trial Results for Imlifidase in Kidney Transplantation

Hansa Biopharma announced successful results from its US Phase 3 ConfIdeS trial for imlifidase, showing significant improvement in kidney function in highly sensitized transplant patients. The positive outcomes, including superior kidney function and dialysis independence, position imlifidase as a potential transformative treatment in kidney transplantation, with plans for a Biologic License Application submission to the FDA by the end of 2025.

Hansa Biopharma to Present at Pareto Healthcare Conference

Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will present at the 16th Annual Pareto Securities Healthcare Conference in Stockholm. The presentation and subsequent panel discussion will address current industry dynamics, including business deals, healthcare system changes, and investor sentiment, potentially impacting the company’s operations and positioning within the biopharmaceutical industry.